White Line Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 03-07-2024
- Paid Up Capital ₹ 7.50 M
as on 03-07-2024
- Company Age 22 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 36.37 M
as on 03-07-2024
- Satisfied Charges ₹ 39.50 M
as on 03-07-2024
- Revenue 32.82%
(FY 2023)
- Profit 41.88%
(FY 2023)
- Ebitda 16.66%
(FY 2023)
- Net Worth 9.44%
(FY 2023)
- Total Assets 11.60%
(FY 2023)
About White Line Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹3.64 Cr. The company has closed loans amounting to ₹3.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kizhakke Sharmil, Cholangady Vinod, and Aramangalam Ramakrishnan serve as directors at the Company.
- CIN/LLPIN
U24231KL2001PTC015134
- Company No.
015134
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Dec 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Kalpetta, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at White Line Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Aramangalam Ramakrishnan  | Managing Director | 21-Dec-2001 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kizhakke Sharmil | Director | 31-Dec-2019 | Current |
| Cholangady Vinod | Director | 21-Dec-2001 | Current |
Financial Performance and Corporate Structure Insights of White Line Pharma.
White Line Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 32.82% increase. The company also saw a substantial improvement in profitability, with a 41.88% increase in profit. The company's net worth moved up by a moderate rise of 9.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of White Line Pharma?
In 2023, White Line Pharma had a promoter holding of 16.00% and a public holding of 84.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jan 2022 | ₹2.10 M | Open |
Others Creation Date: 10 Jun 2020 | ₹4.27 M | Open |
Others Creation Date: 02 Aug 2017 | ₹3.00 Cr | Open |
How Many Employees Work at White Line Pharma?
Unlock and access historical data on people associated with White Line Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Jun 30, 2014, White Line Pharma has raised a total of ₹ 6.02 M, with the most recent deal valued at ₹ 0.5 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
